Osteoporosis vs. Osteopenia

A bone density report can hand you a new word: osteopenia, or osteoporosis. The two sound similar and are easy to confuse. Humanic Blue looks at the dividing line and at the fracture risk that a scan number alone cannot settle.

Osteopenia means bone density is below the young-adult reference range; osteoporosis meets a lower density cutoff or is diagnosed after certain fractures. The distinction comes from a DXA scan, a low-dose X-ray test, and its T-score. For women after menopause and men 50 or older, a score below −1.0 but above −2.5 is low bone mass, often called osteopenia; −2.5 or lower at an accepted hip or spine site meets the scan-based definition of osteoporosis. A hip or vertebral (spinal) fracture can also establish osteoporosis in the appropriate clinical setting regardless of the score. The label alone does not tell someone their chance of breaking a bone.

What separates osteopenia from osteoporosis?

	Osteopenia (low bone mass)	Osteoporosis
T-score in the applicable population	Below −1.0 but above −2.5	−2.5 or lower at the lumbar spine, total hip or femoral neck
Other diagnostic route	Not applicable	Hip or vertebral fracture in the appropriate clinical setting, regardless of BMD
Plain-language meaning	Bone density below the young-adult reference range but not at the osteoporosis cutoff	Bone density at or below the scan-based cutoff, or a qualifying clinical diagnosis
Treatment decision	Fracture history, a FRAX fracture-risk estimate and risks not captured by that tool matter	The BHOF guide describes when to consider medication after clinical evaluation
The catch	Risk varies widely within this range	The cutoff does not capture every person who will fracture

A T-score compares bone density with a healthy young-adult reference, represented by 0. More negative scores mean lower density; they are not percentages of bone lost. The lumbar spine is the lower back; the femoral neck is the narrow part of the thighbone near the hip joint. Total hip refers to a broader area of the upper thighbone measured on the scan.

The T-score categories are summarized by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in its guide to what bone density numbers mean. NIAMS states that fracture risk rises roughly 1.5- to 2-fold for each one-point decrease in T-score. That is a population-level gradient, not an individual’s exact probability.

The International Society for Clinical Densitometry prefers T-scores for postmenopausal women and men age 50 or older. For women before menopause and men younger than 50, it prefers Z-scores, which compare density with people of the same age and sex rather than young adults. A Z-score of −2.0 or lower is described as below the expected range for age. In men younger than 50, bone density alone cannot establish osteoporosis.

Why can the T-score line mislead?

The osteoporosis threshold identifies a group with higher fracture rates, but it cannot identify everyone who will fracture. One reason is distribution: many more people have readings above −2.5 than below it. Age, prior fracture, falls, medications and other clinical factors also change risk.

A well-known demonstration came from the National Osteoporosis Risk Assessment, published in 2004. Researchers followed about 150,000 White postmenopausal women for one year after peripheral bone-density testing—measurements at the heel, finger or forearm rather than the hip and spine. Only 6.4% had T-scores of −2.5 or lower. Although that group had the highest fracture rate, it accounted for 18% of reported new osteoporotic fractures and 26% of hip fractures.

Among the women who reported fractures, 82% had peripheral T-scores above −2.5 and 67% had scores above −2.0. The investigators argued that prevention therefore requires identifying higher-risk women outside the osteoporosis cutoff, not treating the T-score boundary as a complete risk model.

The study used heel, finger or forearm devices rather than central hip-and-spine DXA, relied on reported incident fractures and included only White postmenopausal women. Its percentages should not be generalized to every sex, age or ancestry group. The useful lesson is narrower: a density category alone does not replace fracture-risk assessment.

What does the osteoporosis threshold miss about who will experience a fracture?

How are treatment decisions made beyond the T-score?

The Bone Health and Osteoporosis Foundation’s 2022 Clinician’s Guide lays out when to consider medication in postmenopausal women and men age 50 or older. For preventing a first fracture, it includes:

• A T-score of −2.5 or lower at the hip or spine
• Low bone mass at the femoral neck or total hip with a US-FRAX estimate of at least 3% for hip fracture or at least 20% for a major osteoporotic fracture over 10 years

In FRAX, a major osteoporotic fracture means a fracture of the hip, spine, forearm or upper arm near the shoulder. The FRAX fracture-risk calculator combines age, sex, body size, femoral-neck bone density when available and selected clinical factors to estimate 10-year fracture probability. It does not include every important factor—for example, the number and recency of fractures, falls and frailty (reduced physical reserve and greater vulnerability to illness or injury) may change clinical judgment.

A 3% probability means about 3 in 100 people with similar measured risk factors would be expected to have a hip fracture over 10 years; 20% means about 20 in 100 would have a major osteoporotic fracture. These are group estimates, not predictions of who will fracture.

The guide treats its thresholds as guidance rather than absolute rules. It also recommends treatment after hip or vertebral fracture regardless of BMD, and individualized decisions after certain other fractures in people with low bone mass.

The guide treats a new fracture after 50 as a warning of higher near-term risk, especially during the following year. A 2024 position statement from the American Society for Bone and Mineral Research (ASBMR) and BHOF further emphasizes the recency, number and site of fractures, BMD and other major risk factors when choosing treatment goals and initial therapy. Its evidence comes primarily from older postmenopausal women of European ancestry.

Three members of the guide’s committee report ties to companies that make osteoporosis drugs, including Amgen and Radius Health, according to the guide’s disclosures. The guide was funded by the Bone Health and Osteoporosis Foundation.

Which factors add to a density score when guidelines describe treatment eligibility?

Why this matters for living longer

Fractures, especially of the hip, are linked to a large and lasting rise in the risk of death in older adults, as covered in Protect Bone Density as You Age. That’s why the useful question after a scan isn’t only “Which label do I have?” but “What’s my chance of breaking a bone, and what would lower it?”